ATP5MK and chronic myelogenous leukemia, BCR-ABL1 positive: In a recent study by Jørgensen et al (2002b) investigating a possible link between decreased imatinib efficacy and AGP-drug binding, AGP levels were found to be significantly raised in CML patients at all stages of disease compared to normal controls.